![Emel Çırakoğlu's cover illustration](/_next/image?url=%2F_next%2Fstatic%2Fmedia%2Fdefault-cover.df740e10.webp&w=3840&q=75)
Polygence Scholar2023
![Emel Çırakoğlu's profile](/_next/image?url=https%3A%2F%2Fdpl6hyzg28thp.cloudfront.net%2Fmedia%2Fa4586f40-06c3-48be-9b64-5c0ef59e71a2.jpg&w=640&q=75)
Emel Çırakoğlu
Class of 2022Ankara, Ankara
About
**Hi! My name is Emel. My project is about biomarkers that can detect MS in early stages and gene therapies that can be used as a treatment approach in the future.**Projects
- Gene Therapy With CRISPR-Cas9 To Treat Multiple Sclerosis with mentor Joshua (Sept. 25, 2023)
Project Portfolio
Gene Therapy With CRISPR-Cas9 To Treat Multiple Sclerosis
Started June 20, 2023
![Portfolio item's cover image](/_next/image?url=https%3A%2F%2Fdpl6hyzg28thp.cloudfront.net%2Fmedia%2FEkran-Resmi-2023-09-27-10.19.29.jpeg&w=3840&q=75)
Abstract or project description
Multiple Sclerosis (MS) is a chronic immune-mediated neurodegenerative disease leading to progressive demyelination and atrophy in the brain. This project aims to first briefly highlight immune mediators of the disease, especially regulatory T cells (Tregs). The project will then discuss biomarkers associated with MS, focusing on those expressed by Tregs. Subsequently, the CRISPR-Cas9 system and how it targets genes for deletion, insertion, or replacement will be described. The final part of the project will discuss different targets and delivery methods for CRISPR-Cas9 therapy for MS.